跳至主要内容
临床试验/NCT01354665
NCT01354665已完成不适用

The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.

Bayer0 个研究点目标入组 567 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
567
主要终点
Changes of fatigue score over time

研究概览

简要总结

This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.

The study is conducted in routine practice setting hence no interference with standard care takes place.

Pharmacologic treatments of MS-fatigue and depression will also be recorded.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Relapsing-remitting multiple sclerosis
  • Patients initiating Betaferon treatment

排除标准

  • Patients previously treated with any immunomodulatory drug

结局指标

主要结局

Changes of fatigue score over time

时间窗: short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline

次要结局

  • Changes of depression score over time(short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline)
  • Treatment adherence(12 months)
  • Clinical course of the disease(12 months)
  • Overall treatment tolerability as measured by rate of adverse events(12 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

Depression and Fatigue in MS Patients Treated With... | 临床试验